

Fiona Simpson

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2524773/fiona-simpson-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

56
papers

3,150
citations

26
h-index

56
g-index

64
ext. papers

3,518
ext. citations

6.2
avg, IF

4.58
L-index

#	Paper	IF	Citations
56	Inhibition of the master regulator of <i>Listeria monocytogenes</i> virulence enables bacterial clearance from spacious replication vacuoles in infected macrophages.. <i>PLoS Pathogens</i> , 2022 , 18, e1010166	7.6	0
55	Adenoid cystic carcinoma: a review of clinical features, treatment targets and advances in improving the immune response to monoclonal antibody therapy. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021 , 1875, 188523	11.2	5
54	Epidermal Growth Factor Receptor Expression and Resistance Patterns to Targeted Therapy in Non-Small Cell Lung Cancer: A Review. <i>Cells</i> , 2021 , 10,	7.9	4
53	Evolution of Cancer Vaccines-Challenges, Achievements, and Future Directions. <i>Vaccines</i> , 2021 , 9,	5.3	9
52	Therapeutic implications of immune-profiling and EGFR expression in salivary gland carcinoma. <i>Head and Neck</i> , 2021 , 43, 768-777	4.2	1
51	Germline ERBB3 mutation in familial non-small-cell lung carcinoma: expanding ErbB3 role in oncogenesis. <i>Human Molecular Genetics</i> , 2021 , 30, 2393-2401	5.6	0
50	Cetuximab Exhibits Sex Differences in Lymphatic Exposure after Intravenous Administration in Rats in the Absence of Differences in Plasma Exposure. <i>Pharmaceutical Research</i> , 2020 , 37, 224	4.5	1
49	Scientifically based combination therapies with immuno-oncology checkpoint inhibitors. <i>British Journal of Clinical Pharmacology</i> , 2020 , 86, 1711-1725	3.8	4
48	Endocytosis Inhibition in Humans to Improve Responses to ADCC-Mediating Antibodies. <i>Cell</i> , 2020 , 180, 895-914.e27	56.2	45
47	Immune checkpoint inhibitors in advanced nasopharyngeal carcinoma: Beyond an era of chemoradiation?. <i>International Journal of Cancer</i> , 2020 , 146, 2305-2314	7.5	19
46	Epidermal Growth Factor Receptor3 Function in Cutaneous Squamous Cell Carcinoma and Its Role as a Therapeutic Target in the Age of Immunotherapies. <i>Current Treatment Options in Oncology</i> , 2020 , 21, 9	5.4	3
45	Antibody/Ligand-Target Receptor Internalization Assay Protocol Using Fresh Human or Murine Tumor Samples. <i>STAR Protocols</i> , 2020 , 1, 100087	1.4	
44	Will Next-Generation Immunotherapy Overcome the Intrinsic Diversity and Low Immunogenicity of Sarcomas to Improve Clinical Benefit?. <i>Cancers</i> , 2020 , 12,	6.6	1
43	Cytokine/chemokine profiles in squamous cell carcinoma correlate with precancerous and cancerous disease stage. <i>Scientific Reports</i> , 2019 , 9, 17754	4.9	7
42	An Ex Vivo Human Tumor Assay Shows Distinct Patterns of EGFR Trafficking in Squamous Cell Carcinoma Correlating to Therapeutic Outcomes. <i>Journal of Investigative Dermatology</i> , 2019 , 139, 213-223	4.3	14
41	Clinically-Relevant Rapamycin Treatment Regimens Enhance CD8 Effector Memory T Cell Function In The Skin and Allow their Infiltration into Cutaneous Squamous Cell Carcinoma. <i>Onc Immunology</i> , 2018 , 7, e1479627	7.2	8
40	Characterization of 7A7, an anti-mouse EGFR monoclonal antibody proposed to be the mouse equivalent of cetuximab. <i>Oncotarget</i> , 2018 , 9, 12250-12260	3.3	7

39	Elevated frequencies of CD8 T cells expressing PD-1, CTLA-4 and Tim-3 within tumour from perineural squamous cell carcinoma patients. <i>PLoS ONE</i> , 2017 , 12, e0175755	3.7	24
38	The voltage gated Ca(2+)-channel Cav3.2 and therapeutic responses in breast cancer. <i>Cancer Cell International</i> , 2016 , 16, 24	6.4	24
37	Does the nature of residual immune function explain the differential risk of non-melanoma skin cancer development in immunosuppressed organ transplant recipients?. <i>International Journal of Cancer</i> , 2016 , 138, 281-92	7.5	26
36	Phenothiazine-derived antipsychotic drugs inhibit dynamin and clathrin-mediated endocytosis. <i>Traffic</i> , 2015 , 16, 635-54	5.7	68
35	RacGAP1 Is a Novel Downstream Effector of E2F7-Dependent Resistance to Doxorubicin and Is Prognostic for Overall Survival in Squamous Cell Carcinoma. <i>Molecular Cancer Therapeutics</i> , 2015 , 14, 1939-50	6.1	20
34	A novel E2F/sphingosine kinase 1 axis regulates anthracycline response in squamous cell carcinoma. <i>Clinical Cancer Research</i> , 2015 , 21, 417-27	12.9	23
33	Dysregulation of epidermal growth factor receptor in actinic keratosis and squamous cell carcinoma. <i>Current Problems in Dermatology</i> , 2015 , 46, 20-7		7
32	Phase II study of single-agent panitumumab in patients with incurable cutaneous squamous cell carcinoma. <i>Annals of Oncology</i> , 2014 , 25, 2047-2052	10.3	94
31	Comparative immune phenotypic analysis of cutaneous Squamous Cell Carcinoma and Intraepidermal Carcinoma in immune-competent individuals: proportional representation of CD8+ T-cells but not FoxP3+ Regulatory T-cells is associated with disease stage. <i>PLoS ONE</i> , 2014 , 9, e110928	3.7	28
30	The epidermal growth factor receptor in squamous cell carcinoma: An emerging drug target. <i>Australasian Journal of Dermatology</i> , 2014 , 55, 24-34	1.3	22
29	Household number associated with middle ear disease at an urban Indigenous health service: a cross-sectional study. <i>Australian Journal of Primary Health</i> , 2014 , 20, 285-90	1.4	8
28	Conventionally accepted risk factors do not explain higher rates of middle ear disease in remote Indigenous children: an ecological study. <i>Australian and New Zealand Journal of Public Health</i> , 2012 , 36, 491-2	2.3	2
27	Co-regulation of cell polarization and migration by caveolar proteins PTRF/Cavin-1 and caveolin-1. <i>PLoS ONE</i> , 2012 , 7, e43041	3.7	45
26	Role of intratumoural heterogeneity in cancer drug resistance: molecular and clinical perspectives. <i>EMBO Molecular Medicine</i> , 2012 , 4, 675-84	12	164
25	Clathrin-independent carriers form a high capacity endocytic sorting system at the leading edge of migrating cells. <i>Journal of Cell Biology</i> , 2010 , 190, 675-91	7.3	230
24	Sialic acid modification of adiponectin is not required for multimerization or secretion but determines half-life in circulation. <i>Molecular Endocrinology</i> , 2010 , 24, 229-39		37
23	Adiponectin—it's all about the modifications. <i>International Journal of Biochemistry and Cell Biology</i> , 2010 , 42, 785-8	5.6	74
22	ERp46 binds to AdipoR1, but not AdipoR2, and modulates adiponectin signalling. <i>Biochemical and Biophysical Research Communications</i> , 2010 , 392, 234-9	3.4	49

21	ATF3 and p15PAF are novel gatekeepers of genomic integrity upon UV stress. <i>Cell Death and Differentiation</i> , 2009 , 16, 728-37	12.7	52
20	Trafficking, development and hedgehog. <i>Mechanisms of Development</i> , 2009 , 126, 279-88	1.7	55
19	The coding region of TP53INP2, a gene expressed in the developing nervous system, is not altered in a family with autosomal recessive non-progressive infantile ataxia on chromosome 20q11-q13. <i>Developmental Dynamics</i> , 2007 , 236, 843-52	2.9	13
18	Ca ²⁺ -pumps and Na ²⁺ -Ca ²⁺ -exchangers in coronary artery endothelium versus smooth muscle. <i>Journal of Cellular and Molecular Medicine</i> , 2007 , 11, 129-38	5.6	38
17	Murine embryonic expression of the gene for the UV-responsive protein p15(PAF). <i>Gene Expression Patterns</i> , 2007 , 7, 47-50	1.5	11
16	The PCNA-associated factor KIAA0101/p15(PAF) binds the potential tumor suppressor product p33ING1b. <i>Experimental Cell Research</i> , 2006 , 312, 73-85	4.2	46
15	Visualisation of macropinosome maturation by the recruitment of sorting nexins. <i>Journal of Cell Science</i> , 2006 , 119, 3967-80	5.3	114
14	Evolutionary conservation and murine embryonic expression of the gene encoding the SERTA domain-containing protein CDCA4 (HEPP). <i>Gene</i> , 2006 , 374, 153-65	3.8	13
13	Identification and analysis of novel genes expressed in the mouse embryonic facial primordia. <i>Frontiers in Bioscience - Landmark</i> , 2006 , 11, 2631-46	2.8	7
12	A rapidly evolving secretome builds and patterns a sea shell. <i>BMC Biology</i> , 2006 , 4, 40	7.3	144
11	A novel hook-related protein family and the characterization of hook-related protein 1. <i>Traffic</i> , 2005 , 6, 442-58	5.7	57
10	A novel mammalian retromer component, Vps26B. <i>Traffic</i> , 2005 , 6, 991-1001	5.7	66
9	Characterization of Rab23, a negative regulator of sonic hedgehog signaling. <i>Methods in Enzymology</i> , 2005 , 403, 759-77	1.7	21
8	Characterization of the role of the Rab GTPase-activating protein AS160 in insulin-regulated GLUT4 trafficking. <i>Journal of Biological Chemistry</i> , 2005 , 280, 37803-13	5.4	302
7	Insulin and oleate promote translocation of inosine-5Tmonophosphate dehydrogenase to lipid bodies. <i>Traffic</i> , 2004 , 5, 739-49	5.7	29
6	GLUT4--at the cross roads between membrane trafficking and signal transduction. <i>Traffic</i> , 2001 , 2, 2-11	5.7	87
5	Casein kinase II activity is required for transferrin receptor endocytosis. <i>Journal of Biological Chemistry</i> , 1999 , 274, 30550-6	5.4	22
4	SH3-domain-containing proteins function at distinct steps in clathrin-coated vesicle formation. <i>Nature Cell Biology</i> , 1999 , 1, 119-24	23.4	252

- 3 Phosphatidylinositol-4,5-bisphosphate is required for endocytic coated vesicle formation. *Current Biology*, **1998**, 8, 1399-402 6.3 218
- 2 Characterization of the adaptor-related protein complex, AP-3. *Journal of Cell Biology*, **1997**, 137, 835-457.3 322
- 1 A novel adaptor-related protein complex. *Journal of Cell Biology*, **1996**, 133, 749-60 7.3 207